Outlook Therapeutics to Present at the 2021 American Society of Retina Specialists (ASRS) Annual Meeting
10/07/2021 - 08:05 AM
Suber Huang, MD, MBA, FASRS, will present safety data from Outlook Therapeutics’ NORSE THREE registration trial on Tuesday, October 12, 2021
ISELIN, N.J., Oct. 07, 2021 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company working to develop and launch the first FDA-approved ophthalmic formulation of bevacizumab for use in retinal indications, today announced that Suber S. Huang, MD, MBA, FASRS, Co-Founder and CEO of the Retina Center of Ohio, will present data from Outlook Therapeutics’ NORSE THREE supplemental safety study for ONS-5010 / LYTENAVA™ (bevacizumab-vikg), an investigational ophthalmic formulation of bevacizumab for use in retinal indications. Dr. Huang’s oral presentation will take place at the 2021 Annual Meeting of the American Society of Retina Specialists being held in San Antonio, Texas.
Details for the presentation are as follows:
Safety Results of ONS-5010, an Ophthalmic Bevacizumab, in Treated Eyes of Patients with Wet AMD, DME and BRVO Presenter: Suber S. Huang, MD, MBA, FASRS Date and time: October 12, 2021, at 11:08-11:14 AM CDT
For more information and to register for this event, please visit https://www.asrs.org/annual-meeting.
About the American Society of Retina Specialists
The American Society of Retina Specialists is the largest organization of retina specialists in the world, representing over 3,000 physicians in all 50 US states, the District of Columbia, Puerto Rico, and 63 countries. The Society serves as a national advocate and primary source of clinical and scientific information and education for its members.
About Outlook Therapeutics, Inc.
Outlook Therapeutics is a biopharmaceutical company working to develop and launch ONS-5010/ LYTENAVA™ (bevacizumab-vikg) as the first FDA-approved ophthalmic formulation of bevacizumab for use in retinal indications, including wet AMD, DME and BRVO. If ONS-5010 ophthalmic bevacizumab is approved, Outlook Therapeutics expects to commercialize it as the first and only FDA-approved ophthalmic formulation of bevacizumab for use in treating retinal diseases in the United States, United Kingdom, Europe, Japan and other markets. Outlook Therapeutics expects to submit ONS-5010 ophthalmic bevacizumab to the U.S. FDA as a BLA under the PHSA 351(a) regulatory pathway. For more information, please visit www.outlooktherapeutics.com .
CONTACTS: Media Inquiries: Harriet Ullman Vice President LaVoie Health Science T: 617-669-3082hullman@lavoiehealthscience.com
Investor Inquiries: Jenene Thomas Chief Executive Officer JTC Team, LLC T: 833.475.8247 OTLK@jtcir.com
OTLK Rankings
#4841 Ranked by Stock Gains
OTLK Stock Data
Industry
Biological Product (except Diagnostic) Manufacturing
Sector
Manufacturing
Tags
Health Technology, Biotechnology, Manufacturing, Biological Product (except Diagnostic) Manufacturing
Country
United States
City
Iselin
About OTLK
overview oncobiologics is a pure-play complex biosimilar company focused on technically challenging and commercially attractive monoclonal antibodies (mabs), in the therapeutic areas of immunology and oncology. our strategy is to cost-effectively develop technically challenging biosimilars on an accelerated timeline, which we believe is fundamental to our success and positions us to be a leading biosimilar company. we have leveraged our team’s biopharmaceutical expertise to establish fully integrated in-house development and manufacturing capabilities, which we refer to as our biosymphony™ platform. oncobiologics’ platform addresses the numerous complex technical and regulatory challenges in developing and commercializing mab biosimilars. pipeline oncobiologics is actively working on eight biosimilar candidates. the company’s most advanced assets, ons-3010 (a biosimilar of humira®) and ons-1045 (a biosimilar of avastin®) have both successfully completed phase i trials and phase 3 t